Compare Abeona Therapeutics Inc (ABEO) vs Oscar Health Inc (OSCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Oscar Health Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Oscar Health Inc trades at $30.67 (market cap $9.38B). The key difference: Oscar Health Inc is far larger — about 25.1× Abeona Therapeutics Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | OSCR | |
|---|---|---|
Market Cap | $373.32M | $9.38B |
Sector | Health | Health |
52-Week High | $7.23 | $32.18 |
52-Week Low | $4.17 | $10.85 |
Enterprise Value | $228.22M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Oscar Health (OSCR) trades at $31.44, down 2.3% on the day but showing strong technical momentum with a bullish moving average signal. The company reported a significant Q1 2026 earnings beat with EPS of $2.07 versus $1.21 expected, though full-year 2025 results showed a net loss of $443 million. Revenue growth remains robust, projected to increase from $11.7 billion in 2025 to $13.3 billion in 2026, while operating cash flow improved substantially.
The outlook is mixed: strong revenue growth and positive cash flow support upside potential, but persistent net losses and negative ROE pose fundamental risks. Analyst consensus is cautious with a $22.50 price target below current levels, indicating skepticism about sustainability despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
